Biofrontera AG
Hemmelrather Weg 201
Leverkusen
51377
Germany
Tel: 49-0-214-87632-0
Fax: 49-0-214-87632-90
Website: http://www.biofrontera.com/
Email: info@biofrontera.com
61 articles about Biofrontera AG
-
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
8/29/2023
Biofrontera Inc. announced the appointment of Samantha Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications.
-
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
8/10/2023
Biofrontera Inc. announces that patient enrollment is now complete in the Phase 3 clinical study evaluating Ameluz -PDT in combination with the BF-RhodoLED lamp for the treatment of basal cell carcinoma (BCC).
-
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer
5/30/2023
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert as Chief Executive Officer.
-
Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million
5/11/2023
Biofrontera Inc. announced that it has entered into a $6.5 million secured line of credit with MidCap Business Credit, LLC, subject to the borrowing base formula, minimum excess availability and other terms and conditions.
-
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
4/26/2023
Biofrontera Inc. today announced that that the last patient in a Phase I study to evaluate the safety and tolerability of Ameluz.
-
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting
3/17/2023
Biofrontera Inc. announced that it will be hosting a booth showcasing its innovative, FDA-approved products at the 2023 American Academy of Dermatology Annual Meeting taking place March 17-21, 2023 in New Orleans, LA.
-
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
3/9/2023
This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the press release.
-
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
2/22/2023
Biofrontera Inc. today announced that it will report financial results for the three and 12 months ended December 31, 2022 on Wednesday, March 8, 2023.
-
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
11/30/2022
Biofrontera Inc. announced that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.
-
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
11/14/2022
Biofrontera Inc today announced financial results for the three and nine months ended September 30, 2022 and provided a business update.
-
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
11/8/2022
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the exercise in full of options to purchase 2,623,365 ordinary shares of Biofrontera AG.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
10/24/2022
Biofrontera Inc. announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately.
-
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
10/18/2022
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announces its sponsorship of the Fall Clinical Dermatology Conference, being held October 20-23 in Las Vegas.
-
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
10/14/2022
Biofrontera Inc. announced that its Board of Directors has adopted a limited duration shareholder rights plan, and declared a dividend distribution of one preferred stock purchase right on each outstanding share of common stock, in order to protect the interest of all of the Company’s shareholders.
-
Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
10/5/2022
Biofrontera Inc. today announced preliminary unaudited product revenues for the three and nine months ended September 30, 2022.
-
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
9/26/2022
Biofrontera Inc. announced that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards.
-
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
-
Biofrontera Inc.’s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
8/18/2022
Biofrontera Inc. announced that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has named Leslie Hopkins, Associate Director of Marketing, as a Trailblazer Brand Champion in the Dermatology category.
-
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
8/1/2022
Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Australian Patent Office (IP Australia) granted a notice of allowance to Biofrontera Bioscience GmbH for the patent "Photodynamic therapy comprising two light exposures at different wavelengths" (AU 2018/437303B2).